Loading…

Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis

Randomized controlled trial. To characterize the increase in gelatinase A (MMP2) activity after spinal cord injury (SCI) in the mouse model, and the effects of MMP2/MMP9 inhibition on apoptotic cells. Clinical consequences of SCI are due to a series of secondary injury cascades. Matrix metalloprotei...

Full description

Saved in:
Bibliographic Details
Published in:Spine (Philadelphia, Pa. 1976) Pa. 1976), 2008-08, Vol.33 (17), p.E576-E579
Main Authors: Dang, Alexis B C, Tay, Bobby K-B, Kim, Hubert T, Nauth, Aaron, Alfonso-Jaume, Maria Alexandra, Lovett, David H
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23
cites cdi_FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23
container_end_page E579
container_issue 17
container_start_page E576
container_title Spine (Philadelphia, Pa. 1976)
container_volume 33
creator Dang, Alexis B C
Tay, Bobby K-B
Kim, Hubert T
Nauth, Aaron
Alfonso-Jaume, Maria Alexandra
Lovett, David H
description Randomized controlled trial. To characterize the increase in gelatinase A (MMP2) activity after spinal cord injury (SCI) in the mouse model, and the effects of MMP2/MMP9 inhibition on apoptotic cells. Clinical consequences of SCI are due to a series of secondary injury cascades. Matrix metalloproteinases are thought play a key role in this, leading to apoptotic cell death. SCI via a drop tower in mice was used. MMP2 beta-gal reporter mice were used to quantify the level of MMP2 after SCI. In a follow-up experiment, mice which underwent SCI were randomized to daily SQ injections of MMP2/MMP9 inhibitor versus placebo. MMP2 levels were quantified and histology was performed with TUNEL and Luxol fast blue staining. MMP2 transcription was significantly upregulated after SCI, by the beta-gal assay. Inhibition of MMP2/MMP9 activity after SCI led to statistically significant decreases in apoptosis within the zone of injury. There was a trend towards preservation of myelin by preserved luxol fast blue staining. After SCI, MMP2 is upregulated along with neuron and glial cells apoptosis. The level of apoptosis could be reduced with MMP2/MMP9 inhibition. This supports MMP2 as cause for apoptosis after SCI with the potential for therapeutic intervention as apoptosis can be reduced with MMP2 inhibition.
doi_str_mv 10.1097/brs.0b013e31817ecc87
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69374841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69374841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23</originalsourceid><addsrcrecordid>eNpdkMtOwzAURC0EoqXwBwh5xS7tvbGTOEta8ajUCsRjHdnOtQjKCztZ8PcEUQmJWcxsZmZxGLtEWCLk2cr4sAQDKEigwoysVdkRm2MSqwgxyY_ZHEQaR7EU6YydhfABAKnA_JTNUKUZiFjO2XrbvlemGqqu5Z3j-_1TvJos59oN5Hnoq1bX3Ha-5IPXY6O5p3K0FLjuu37oQhXO2YnTdaCLQy7Y293t6-Yh2j3ebzc3u8iKDIfIaUiMs4bAkKNSostzyAlLILRpaskp7XRqpJE4yaqEAGRCFCsRJ2UsFuz697f33edIYSiaKliqa91SN4YizUUmlcSpKH-L1ncheHJF76tG-68CofhhV6yfX4r_7KbZ1eF_NA2Vf6MDLPENcapsEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69374841</pqid></control><display><type>article</type><title>Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><creator>Dang, Alexis B C ; Tay, Bobby K-B ; Kim, Hubert T ; Nauth, Aaron ; Alfonso-Jaume, Maria Alexandra ; Lovett, David H</creator><creatorcontrib>Dang, Alexis B C ; Tay, Bobby K-B ; Kim, Hubert T ; Nauth, Aaron ; Alfonso-Jaume, Maria Alexandra ; Lovett, David H</creatorcontrib><description>Randomized controlled trial. To characterize the increase in gelatinase A (MMP2) activity after spinal cord injury (SCI) in the mouse model, and the effects of MMP2/MMP9 inhibition on apoptotic cells. Clinical consequences of SCI are due to a series of secondary injury cascades. Matrix metalloproteinases are thought play a key role in this, leading to apoptotic cell death. SCI via a drop tower in mice was used. MMP2 beta-gal reporter mice were used to quantify the level of MMP2 after SCI. In a follow-up experiment, mice which underwent SCI were randomized to daily SQ injections of MMP2/MMP9 inhibitor versus placebo. MMP2 levels were quantified and histology was performed with TUNEL and Luxol fast blue staining. MMP2 transcription was significantly upregulated after SCI, by the beta-gal assay. Inhibition of MMP2/MMP9 activity after SCI led to statistically significant decreases in apoptosis within the zone of injury. There was a trend towards preservation of myelin by preserved luxol fast blue staining. After SCI, MMP2 is upregulated along with neuron and glial cells apoptosis. The level of apoptosis could be reduced with MMP2/MMP9 inhibition. This supports MMP2 as cause for apoptosis after SCI with the potential for therapeutic intervention as apoptosis can be reduced with MMP2 inhibition.</description><identifier>ISSN: 0362-2436</identifier><identifier>EISSN: 1528-1159</identifier><identifier>DOI: 10.1097/brs.0b013e31817ecc87</identifier><identifier>PMID: 18670324</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Apoptosis - drug effects ; Apoptosis - physiology ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Matrix Metalloproteinase 2 - biosynthesis ; Matrix Metalloproteinase 2 - genetics ; Matrix Metalloproteinase 9 - biosynthesis ; Matrix Metalloproteinase 9 - genetics ; Matrix Metalloproteinase Inhibitors ; Mice ; Mice, Transgenic ; Neuroglia - enzymology ; Neuroglia - pathology ; Neurons - enzymology ; Neurons - pathology ; Random Allocation ; Spinal Cord Injuries - drug therapy ; Spinal Cord Injuries - enzymology ; Spinal Cord Injuries - pathology ; Up-Regulation - genetics</subject><ispartof>Spine (Philadelphia, Pa. 1976), 2008-08, Vol.33 (17), p.E576-E579</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23</citedby><cites>FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18670324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dang, Alexis B C</creatorcontrib><creatorcontrib>Tay, Bobby K-B</creatorcontrib><creatorcontrib>Kim, Hubert T</creatorcontrib><creatorcontrib>Nauth, Aaron</creatorcontrib><creatorcontrib>Alfonso-Jaume, Maria Alexandra</creatorcontrib><creatorcontrib>Lovett, David H</creatorcontrib><title>Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis</title><title>Spine (Philadelphia, Pa. 1976)</title><addtitle>Spine (Phila Pa 1976)</addtitle><description>Randomized controlled trial. To characterize the increase in gelatinase A (MMP2) activity after spinal cord injury (SCI) in the mouse model, and the effects of MMP2/MMP9 inhibition on apoptotic cells. Clinical consequences of SCI are due to a series of secondary injury cascades. Matrix metalloproteinases are thought play a key role in this, leading to apoptotic cell death. SCI via a drop tower in mice was used. MMP2 beta-gal reporter mice were used to quantify the level of MMP2 after SCI. In a follow-up experiment, mice which underwent SCI were randomized to daily SQ injections of MMP2/MMP9 inhibitor versus placebo. MMP2 levels were quantified and histology was performed with TUNEL and Luxol fast blue staining. MMP2 transcription was significantly upregulated after SCI, by the beta-gal assay. Inhibition of MMP2/MMP9 activity after SCI led to statistically significant decreases in apoptosis within the zone of injury. There was a trend towards preservation of myelin by preserved luxol fast blue staining. After SCI, MMP2 is upregulated along with neuron and glial cells apoptosis. The level of apoptosis could be reduced with MMP2/MMP9 inhibition. This supports MMP2 as cause for apoptosis after SCI with the potential for therapeutic intervention as apoptosis can be reduced with MMP2 inhibition.</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Matrix Metalloproteinase 2 - biosynthesis</subject><subject>Matrix Metalloproteinase 2 - genetics</subject><subject>Matrix Metalloproteinase 9 - biosynthesis</subject><subject>Matrix Metalloproteinase 9 - genetics</subject><subject>Matrix Metalloproteinase Inhibitors</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Neuroglia - enzymology</subject><subject>Neuroglia - pathology</subject><subject>Neurons - enzymology</subject><subject>Neurons - pathology</subject><subject>Random Allocation</subject><subject>Spinal Cord Injuries - drug therapy</subject><subject>Spinal Cord Injuries - enzymology</subject><subject>Spinal Cord Injuries - pathology</subject><subject>Up-Regulation - genetics</subject><issn>0362-2436</issn><issn>1528-1159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpdkMtOwzAURC0EoqXwBwh5xS7tvbGTOEta8ajUCsRjHdnOtQjKCztZ8PcEUQmJWcxsZmZxGLtEWCLk2cr4sAQDKEigwoysVdkRm2MSqwgxyY_ZHEQaR7EU6YydhfABAKnA_JTNUKUZiFjO2XrbvlemGqqu5Z3j-_1TvJos59oN5Hnoq1bX3Ha-5IPXY6O5p3K0FLjuu37oQhXO2YnTdaCLQy7Y293t6-Yh2j3ebzc3u8iKDIfIaUiMs4bAkKNSostzyAlLILRpaskp7XRqpJE4yaqEAGRCFCsRJ2UsFuz697f33edIYSiaKliqa91SN4YizUUmlcSpKH-L1ncheHJF76tG-68CofhhV6yfX4r_7KbZ1eF_NA2Vf6MDLPENcapsEQ</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Dang, Alexis B C</creator><creator>Tay, Bobby K-B</creator><creator>Kim, Hubert T</creator><creator>Nauth, Aaron</creator><creator>Alfonso-Jaume, Maria Alexandra</creator><creator>Lovett, David H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis</title><author>Dang, Alexis B C ; Tay, Bobby K-B ; Kim, Hubert T ; Nauth, Aaron ; Alfonso-Jaume, Maria Alexandra ; Lovett, David H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Matrix Metalloproteinase 2 - biosynthesis</topic><topic>Matrix Metalloproteinase 2 - genetics</topic><topic>Matrix Metalloproteinase 9 - biosynthesis</topic><topic>Matrix Metalloproteinase 9 - genetics</topic><topic>Matrix Metalloproteinase Inhibitors</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Neuroglia - enzymology</topic><topic>Neuroglia - pathology</topic><topic>Neurons - enzymology</topic><topic>Neurons - pathology</topic><topic>Random Allocation</topic><topic>Spinal Cord Injuries - drug therapy</topic><topic>Spinal Cord Injuries - enzymology</topic><topic>Spinal Cord Injuries - pathology</topic><topic>Up-Regulation - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dang, Alexis B C</creatorcontrib><creatorcontrib>Tay, Bobby K-B</creatorcontrib><creatorcontrib>Kim, Hubert T</creatorcontrib><creatorcontrib>Nauth, Aaron</creatorcontrib><creatorcontrib>Alfonso-Jaume, Maria Alexandra</creatorcontrib><creatorcontrib>Lovett, David H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Spine (Philadelphia, Pa. 1976)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dang, Alexis B C</au><au>Tay, Bobby K-B</au><au>Kim, Hubert T</au><au>Nauth, Aaron</au><au>Alfonso-Jaume, Maria Alexandra</au><au>Lovett, David H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis</atitle><jtitle>Spine (Philadelphia, Pa. 1976)</jtitle><addtitle>Spine (Phila Pa 1976)</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>33</volume><issue>17</issue><spage>E576</spage><epage>E579</epage><pages>E576-E579</pages><issn>0362-2436</issn><eissn>1528-1159</eissn><abstract>Randomized controlled trial. To characterize the increase in gelatinase A (MMP2) activity after spinal cord injury (SCI) in the mouse model, and the effects of MMP2/MMP9 inhibition on apoptotic cells. Clinical consequences of SCI are due to a series of secondary injury cascades. Matrix metalloproteinases are thought play a key role in this, leading to apoptotic cell death. SCI via a drop tower in mice was used. MMP2 beta-gal reporter mice were used to quantify the level of MMP2 after SCI. In a follow-up experiment, mice which underwent SCI were randomized to daily SQ injections of MMP2/MMP9 inhibitor versus placebo. MMP2 levels were quantified and histology was performed with TUNEL and Luxol fast blue staining. MMP2 transcription was significantly upregulated after SCI, by the beta-gal assay. Inhibition of MMP2/MMP9 activity after SCI led to statistically significant decreases in apoptosis within the zone of injury. There was a trend towards preservation of myelin by preserved luxol fast blue staining. After SCI, MMP2 is upregulated along with neuron and glial cells apoptosis. The level of apoptosis could be reduced with MMP2/MMP9 inhibition. This supports MMP2 as cause for apoptosis after SCI with the potential for therapeutic intervention as apoptosis can be reduced with MMP2 inhibition.</abstract><cop>United States</cop><pmid>18670324</pmid><doi>10.1097/brs.0b013e31817ecc87</doi></addata></record>
fulltext fulltext
identifier ISSN: 0362-2436
ispartof Spine (Philadelphia, Pa. 1976), 2008-08, Vol.33 (17), p.E576-E579
issn 0362-2436
1528-1159
language eng
recordid cdi_proquest_miscellaneous_69374841
source HEAL-Link subscriptions: Lippincott Williams & Wilkins
subjects Animals
Apoptosis - drug effects
Apoptosis - physiology
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Matrix Metalloproteinase 2 - biosynthesis
Matrix Metalloproteinase 2 - genetics
Matrix Metalloproteinase 9 - biosynthesis
Matrix Metalloproteinase 9 - genetics
Matrix Metalloproteinase Inhibitors
Mice
Mice, Transgenic
Neuroglia - enzymology
Neuroglia - pathology
Neurons - enzymology
Neurons - pathology
Random Allocation
Spinal Cord Injuries - drug therapy
Spinal Cord Injuries - enzymology
Spinal Cord Injuries - pathology
Up-Regulation - genetics
title Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A32%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20MMP2/MMP9%20after%20spinal%20cord%20trauma%20reduces%20apoptosis&rft.jtitle=Spine%20(Philadelphia,%20Pa.%201976)&rft.au=Dang,%20Alexis%20B%20C&rft.date=2008-08-01&rft.volume=33&rft.issue=17&rft.spage=E576&rft.epage=E579&rft.pages=E576-E579&rft.issn=0362-2436&rft.eissn=1528-1159&rft_id=info:doi/10.1097/brs.0b013e31817ecc87&rft_dat=%3Cproquest_cross%3E69374841%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-fa05bfcbe0befed41f9909e1d0e1c66cef8afa6b4b41111c85e0045ee28325d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69374841&rft_id=info:pmid/18670324&rfr_iscdi=true